Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Jonathan Alspaugh, insider at Aeglea BioTherapeutics
Jonathan Alspaugh Insider Alerts

Get notified the next time Jonathan Alspaugh buys or sells Aeglea BioTherapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Jonathan Alspaugh Insider Information

Jonathan Alspaugh has over a decade of experience advising healthcare companies on strategic and financial matters. Jonathan joined Aeglea from Evercore where he most recently served as a managing director in the firm’s corporate advisory business. At Evercore, Jonathan was involved in numerous strategic transactions including advising Bristol-Myers Squibb on its acquisition of Celgene, Akebia on its merger with Keryx, PTC Therapeutics on its acquisition of Emflaza, and dozens of successful equity financings to support the strategic growth of clients in the biopharma space. Prior to Evercore, Jonathan was a member of Barclays Capital’s global healthcare investment banking team. Previously, Jonathan served in the United States Marine Corps infantry. Jonathan received an S.M. from the Harvard-MIT Division of Health Sciences and Technology, an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management and a B.S.E. and an M.S.E. in Nuclear Engineering and Radiological Sciences from the University of Michigan.

How do I contact Jonathan Alspaugh?

The corporate mailing address for Mr. Alspaugh and other Aeglea BioTherapeutics executives is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. Aeglea BioTherapeutics can also be reached via phone at (512) 942-2935 and via email at [email protected]

Has Jonathan Alspaugh been buying or selling shares of Aeglea BioTherapeutics?

Jonathan Alspaugh has not been actively trading shares of Aeglea BioTherapeutics over the course of the past ninety days. Most recently, on Wednesday, August 18th, Jonathan Alspaugh bought 7,200 shares of Aeglea BioTherapeutics stock. The stock was acquired at an average cost of $6.72 per share, with a total value of $48,384.00.

Are insiders buying or selling shares of Aeglea BioTherapeutics?

During the last year, Aeglea BioTherapeutics insiders bought shares 2 times. They purchased a total of 16,980 shares worth more than $110,682.60. The most recent insider tranaction occured on August, 18th when CFO Jonathan Alspaugh bought 7,200 shares worth more than $48,384.00. Insiders at Aeglea BioTherapeutics own 3.8 % of the company.

Information on this page was last updated on 8/18/2021.

Jonathan Alspaugh Insider Trading History at Aeglea BioTherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2021Buy7,200$6.72$48,384.00View SEC Filing Icon  
8/16/2021Buy9,780$6.37$62,298.60View SEC Filing Icon  
See Full Table

Jonathan Alspaugh Buying and Selling Activity at Aeglea BioTherapeutics

This chart shows Jonathan Alspaugh's buying and selling at Aeglea BioTherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aeglea BioTherapeutics Company Overview

Aeglea BioTherapeutics logo
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $6.08
Low: $6.03
High: $6.57

50 Day Range

MA: $7.44
Low: $6.08
High: $8.42

2 Week Range

Now: $6.08
Low: $5.82
High: $9.78

Volume

188,331 shs

Average Volume

144,599 shs

Market Capitalization

$299.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47
Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply